SeaStar Medical
ICU
Market cap $16.9M

4.02 USD

-0.18

4.29%

At close Oct 17, 4:00 PM EDT

After hours

4.03

+0.01

0.25%

1 day

-4.29%

5 days

1.01%

1 month

-20.71%

3 months

-48.26%

6 months

-77.02%

Year to date

-65.34%

1 year

-64.55%

5 years

-98.52%

About: SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Employees: 12

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

2.46% less ownership

Funds ownership: 8.02% [Q1] → 5.56% (-2.46%) [Q2]

47% less funds holding

Funds holding: 30 [Q1] → 16 (-14) [Q2]

70% less capital invested

Capital invested by funds: $3.87M [Q1] → $1.16M (-$2.71M) [Q2]

78% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 18

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 10

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ICU.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ICU published over the past 30 days

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

DENVER, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the presentation of new analyses of clinical data further supporting the immunomodulating effect of the Selective Cytopheretic Device (SCD) at the American Society of Nephrology (ASN) 2024 Kidney Week to be held October 24-27 in San Diego. Abstracts for the meeting are available here.

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

DENVER, Oct. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit hosted by M-Vest on Wednesday, October 16, at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The fireside chat will be hosted by Maxim Group analyst Anthony Vendetti.

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the activation of Brooke Army Medical Center (BAMC) and the United States Army Institute of Surgical Research (USAISR), expanding the number of sites in its NEUTRALIZE-AKI pivotal trial. This trial is evaluating the safety and efficacy of SeaStar Medical's innovative Selective Cytopheretic Device (SCD) in treating acute kidney injury (AKI) in adult ICU patients receiving continuous kidney replacement therapy (CKRT). With the inclusion of these prestigious military medical facilities, SeaStar Medical now has 11 active clinical sites with 48 subjects enrolled to date.

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

DENVER, Sept. 25, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the enrollment of four additional subjects in a 10-day period in its pivotal NEUTRALIZE-AKI trial, bringing total trial enrollment to 46. This trial is evaluating the safety and efficacy of SeaStar Medical's proprietary therapeutic Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI) in the intensive care unit (ICU) receiving continuous kidney replacement therapy (CKRT).

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against SeaStar Medical Holding Corporation

LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 6, 2024.

The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation Is Being Sued For Violating Securities Regulations And Stockholders Are Invited To Help The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 6, 2024.

SeaStar Medical Holding Corporation Is Being Sued For Violating Securities Regulations And Stockholders Are Invited To Help The Schall Law Firm

The Schall Law Firm Urges Investors To Take Part In A Securities Fraud Case Against SeaStar Medical Holding Corporation

LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 6, 2024.

The Schall Law Firm Urges Investors To Take Part In A Securities Fraud Case Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation Is Being Sued For Securities Law Violations And Stakeholders Are Invited To Reach Out To The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 6, 2024.

SeaStar Medical Holding Corporation Is Being Sued For Securities Law Violations And Stakeholders Are Invited To Reach Out To The Schall Law Firm

The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against SeaStar Medical Holding Corporation

LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 6, 2024.

The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation Is Being Sued For Securities Law Violations And Stakeholders Are Invited To Help The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 6, 2024.

SeaStar Medical Holding Corporation Is Being Sued For Securities Law Violations And Stakeholders Are Invited To Help The Schall Law Firm

See News Rankings

Charts implemented using Lightweight Charts™